Christopher J. Soares
24Patents
11h-index
38Co-inventors
75Inventor score
Filing activity: Apr 23, 1992 → Jun 14, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5261923A | Method and apparatus for continuous circular capsulorehexis | Human Necessities | 74 | Expired |
| US8263545B2 | GIP analog and hybrid polypeptides with selectable properties | Human Necessities | 57 | Active |
| US8076288B2 | Hybrid polypeptides having glucose lowering activity | Human Necessities | 44 | Active |
| US8759295B2 | Peptide-peptidase inhibitor conjugates and methods of using same | Human Necessities | 32 | Active |
| US8114958B2 | Amylin family peptides | Human Necessities | 23 | Active |
| US8497240B2 | DPP-IV resistant GIP hybrid polypeptides with selectable properties | Chemistry; Metallurgy | 21 | Active |
| US6479492B1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | Emerging Cross-Sectional Technologies | 20 | Expired |
| US6903088B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | Emerging Cross-Sectional Technologies | 17 | Expired |
| US8697647B2 | Hybrid polypeptides with selectable properties | Human Necessities | 16 | Active |
| US8598120B2 | Methods for treatment using amylin family peptides | Human Necessities | 15 | Active |
| US8404637B2 | GIP analog and hybrid polypeptides with selectable properties | Chemistry; Metallurgy | 15 | Expired |
| US9193776B2 | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use | Human Necessities | 4 | Active |
| US9217022B2 | GLP-1 receptor agonist compounds having stabilized regions | Emerging Cross-Sectional Technologies | 3 | Active |
| US10370425B2 | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use | Human Necessities | 2 | Active |
| US9593154B2 | Engineered polypeptides having enhanced duration of action | Chemistry; Metallurgy | 2 | Active |
| US8598314B2 | Peptide-peptidase-inhibitor conjugates and methods of making and using same | Human Necessities | 2 | Active |
| US11390654B2 | Use of CGRP receptor antagonists in neuroprotection and neurological disorders | Emerging Cross-Sectional Technologies | 1 | Active |
| US9133260B2 | GIP analog and hybrid polypeptides with selectable properties | Chemistry; Metallurgy | 0 | Active |
| US9453063B2 | Hybrid polypeptides with selectable properties | Human Necessities | 0 | Active |
| US7538215B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | Emerging Cross-Sectional Technologies | 0 | Expired |
| US9951115B2 | CGRP agonist peptides | Human Necessities | 0 | Active |
| US8895498B2 | GIP and exendin hybrid polypeptides | Human Necessities | 0 | Active |
| US9721485B2 | Freight removal regulation apparatus | Performing Operations; Transporting | 0 | Active |
| US12103951B2 | Use of CGRP receptor antagonists in neuroprotection and neurological disorders | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.